

Edgar Filing: ANDO GORAN - Form 5

ANDO GORAN
Form 5
February 15, 2002

FORM 5

Check box if no longer subject to
Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).

Form 3 Holdings Reported

Form 4 Transactions Reported

OMB APPROVAL

OMB Number: 323
Expires: December 31
Estimated average bu
hours per response..

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of t
Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of

1. Name and Address of Reporting Person*

2. Issuer Name and Ticker

Ando, Goran

Pharmacia Co

(Last) (First) (Middle)

3. I.R.S. Identification
Number of Reporting
Person, if an entity
(Voluntary)

100 Route 206 North

(Street)

Peapack, NJ 07977

(City) (State) (Zip)

6. Relationship of Reporting Person(s) to Issuer
(Check all Applicable)

Director

10% Owner

Edgar Filing: ANDO GORAN - Form 5

*If the form is filed by more than one reporting person, see Instruction 4(b)(v).

(Over)
SEC 2270 (3-99)

Page 1 of 3

FORM 5 (continued)

Ando, Goran - December 2001

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date and Exercise Price (Mo)
				(A)	(D)	
Option (right to buy)	\$49.10	04/02/2001	A	2,036		(3)
Option (right to buy)	\$49.10	04/02/2011	A	107,964		(4)
Option (right to buy)	\$45.90					(5)
Option (right to buy)	\$33.64					(5)
Option (right to buy)	\$51.59					(4)
Option (right to buy)	\$41.23					(5)
Performance Share Units	1-for-1					(6)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned at	10. Ownership of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr.
---	--	--	--	---

Edgar Filing: ANDO GORAN - Form 5

End of
Year
(Instr. 4) (I)
(Instr. 4)

Title	Amount or Number of Shares		
Common	2,036		D
Common	107,964	110,000	D
Common	119,000	119,000	D
Common	47,500	47,500	D
Common	125,000	125,000	D
Common	119,000	119,000	D
Common	100,000	100,000	

Explanation of Responses:

See attached statement

**Intentional misstatements or omissions of facts constitute Federal Criminal Violations.

See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Don W. Schmitz	2/14/2002
-----	-----
** Signature of Reporting Person Don W. Schmitz, attorney-in-fact for Goran Ando	Date

Edgar Filing: ANDO GORAN - Form 5

Pharmacia Corporation PHA

Form 5 - December 2001

Ando, Goran
100 Route 206 North
Peapack, NJ 07977

Explanation of responses:

- (1) Includes 6,702 shares held in a Deferred Compensation Plan, including 278 deferred dividends equivalents on such shares.
- (2) Includes 1000 shares acquired in the Pharmacia & Upjohn Savings Plan and Pharmacia Savings Plus since last reported to the SEC.
- (3) Option exercisable on 4/02/2004
- (4) Option becomes exercisable for one-third of the shares on the first, second and third anniversary of the grant date.
- (5) Option is currently exercisable.
- (6) Performance share units will be earned on the earlier of 12/31/04 (unless employment terminates) or the date of change-in-control with the ultimate payout in the range of 0% to 125% of the number of units granted based upon the Company's relative total shareholder return compared to peer companies and absolute total shareholder return over the performance period.

Page 3 of 3